FDA Approves Eyla: A New Eye Drug for Diabetic Patients

The decision was made based on two phase 3 clinical trials. These trials included 862 patients and compared Eylea 2 mg given every month, given every two months after five initial monthly injection, and macular laser photocoagulation. In both trials, Eylea demonstrated a significant improvement in diabetic retinopathy in patients with DME after two years of treatment.

Read more

Posted in Drugs